Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Rosiglitazone Treatment and Secondary Prevention of Cardiovascular Events in Patients With Pre-Diabetes Mellitus and Coronary Artery Disease

NCT01574820 is registered in ClinicalTrials.gov with National Cheng-Kung University Hospital as lead sponsor.

NCT NCT01574820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01574820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Rosiglitazone Treatment and Secondary Prevention of Cardiovascular Events in Patients With Pre-Diabetes Mellitus and Coronary Artery Disease
Lead sponsor
National Cheng-Kung University Hospital
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
July 31, 2011
Enrollment
105 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, glucose intolerance, insulin resistance, prediabetes